| Budget Amount *help |
¥3,770,000 (Direct Cost: ¥2,900,000、Indirect Cost: ¥870,000)
Fiscal Year 2024: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2023: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2022: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
|
|---|
| Outline of Annual Research Achievements |
論文業績①Ceramide synthase CERS4 gene downregulation is associated with KRAS mutation in colorectal cancer. Tamuro Hayama, Kotaro Hama, Tsuyoshi Ozaw, Yuko Fujiwara, Keijiro Nozawa, Keiji Matsuda, Kazuaki Yokoyama, Yojiro Hashiguchi, Hiroki Ochiai , Takeyuki Misawa, Takeo Fukagawa. Sci Rep. 2023 Sep 27;13(1):16249. doi:10.1038/s41598-023-43557-1.
②Prognostic Value of KRAS Exon-specific Mutations in Patients With Colorectal Cancer. Kentaro Asako, Tamuro Hayama, Yojiro Hashiguchi, Toshiya Miyata, Yoshihisa Fukushima, Ryu Shimada, Kensuke Kaneko, Keijiro Nozawa, Keiji Matsuda, Takeo Fukagawa. Anticancer Res. 2023 Apr;43(4):1563-1568. doi: 10.21873/anticanres.16306.
③Predicting prognosis in colorectal cancer patients with curative resection using albumin, lymphocyte count and RAS mutations. Toshiya Miyata, MD, Tamuro Hayama, MD, PhD, Tsuyoshi Ozawa, MD, PhD, Keijiro Nozawa, MD, PhD, Takeyuki Misawa, MD, PhD, Takeo Fukagawa, MD, PhD. scentific reports (投稿中)
学会発表①「大腸癌に対して治癒切除を施行した患者におけるNaples Prognostic Scoreの有用性の検討」日本大腸肛門病学会②「当院における若年者大腸癌の臨床病理学的検討(」日本大腸肛門病学会③「吸収性癒着防止フィルムによる腹腔鏡下大腸癌手術後の小腸閉塞予防効果 傾向スコアマッチングによる比較検証」日本大腸肛門病学会④「大腸癌患者における再発予測因子としてのadvanced lung cancer inflammation indexの有用性について」日本消化器外科学会
|
